NEW YORK — Pharmaceutical giants, fresh off news of a single Alzheimer's patient speaking in full sentences after taking psilocybin, announced Monday a groundbreaking initiative to develop a safe and — crucially — incredibly expensive version of the naturally occurring fungi. The multi-billion-dollar "Project Myco-Profit" aims to transform common magic mushrooms into a proprietary drug by approximately 2054, ensuring maximum shareholder returns and limited accessibility.
"While it's exciting to see raw, unregulated botanicals show glimmers of promise, our mission is to deliver 'scientifically validated, financially viable solutions'," stated Dr. Reginald 'Reggie' Thorne, CEO of BioPharma Corp, speaking from his yacht docked off Monaco. "Turning a five-dollar mushroom into a $75,000 annual treatment requires careful, painstaking research. And, of course, a robust intellectual property portfolio that justifies that valuation." Dr. Thorne outlined an exhaustive three-decade development process, including 15 phases of clinical trials, 20 unique branding campaigns, and a minimum of 40 separate lobbyist-funded congressional hearings to overturn decades of 'demon weed' rhetoric.
The research, funded by a consortium of major pharmaceutical companies, will focus primarily on isolating the specific psychoactive compound, then "enhancing" it with proprietary fillers, packaging it into a tamper-proof, single-dose pill, and then making it utterly unaffordable without top-tier insurance or a second mortgage. "We can't just let people forage for their own cures; where's the patient safety in that?" added Thorne, gesturing to a tray of artisanal truffle fries. "Our trials will confirm what we already know: that efficacy dramatically increases when dispensed by a licensed professional in a sterile, profit-generating environment. The public needs protection from, well, affordable solutions."
A leaked internal memo, obtained by Hambry, detailed the project’s internal projections. "Our goal is not merely a cure, but a scalable, revenue-generating ecosystem," the memo read. "We project initial treatment costs will align with cutting-edge cancer therapies, gradually decreasing only after patent expiration or if a competitor manages to synthesize an equally expensive version." The memo also highlighted the "immense PR challenge" of reversing sixty years of government-sponsored misinformation campaigns against psychedelics, noting, "It’s much easier to demonize a drug until we figure out how to monetize it."
Skeptics pointed out the 30-year timeline means most currently suffering Alzheimer's patients will not benefit from this specific iteration. However, a spokesperson for the Pharmaceutical Research and Manufacturers of America (PhRMA) clarified, "The real beneficiaries are our shareholders, whose patience and investment make this all possible. Plus, think of all the new research jobs. It's an economic stimulus for the next three decades, all leading to a cure that, once patented, will reshape the entire healthcare industry's balance sheet for the fortunate few."
The first phase of clinical trials, titled "Consumer Willingness to Pay for a Slightly Smaller Pill," is slated to begin in 2030, with enrollment limited to billionaires’ grandparents or those with 'exceptional' insurance coverage.
